Market research
NXOA.F Nicox S.A
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.51
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0013018124
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.51
About
About Nicox S.A
Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. It develops solutions to preserving vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, an investigational ophthalmic treatment based on fluticasone propionate that is in Phase 2 clinical trial for the treatment of dry eye disease; and NCX 1728, a NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NXOA.F discussion.
5 years, 5 months ago
Nicox S.A is currently in a long term downtrend where the price is trading 12.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.3.
Nicox S.A's total revenue sank by 0.0% to $632K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 0.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Nicox S.A gets an overall score of 2/5.